HIOC


HIOC is a small-molecule agent which acts as a selective TrkB receptor agonist. It was derived from N-acetylserotonin. Relative to NAS, HIOC possesses greater potency and a longer half-life. It is described as producing long-lasting activation of the TrkB receptor and downstream signaling kinases associated with the receptor. HIOC is systemically-active and is able to penetrate the blood-brain-barrier. In animal studies, HIOC was found to robustly protect against glutamate-induced excitotoxicity, an action which was TrkB-dependent.
A chemical synthesis of HIOC has been published in 2015.